Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
michael.youdell@oncology.ox.ac.uk

Research groups

CRUK Oxford Centre

BRC: Multi-modal Cancer Therapies

Oxford Molecular Diagnostics Centre

Michael Youdell

Project Manager

CRUK Oxford Centre

Biography

I became a Project Manager in Medical Sciences after completing Undergraduate and Postgraduate training in Biochemistry at Oxford University.

Recent publications

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.

Milotay G. et al, (2025), Nat Med, 31, 2350 - 2364

Tumour purity assessment with deep learning in colorectal cancer and impact on molecular analysis.

Schoenpflug LA. et al, (2025), J Pathol, 265, 184 - 197

Cytomegalovirus infection protects against metastatic melanoma and modulates oncological outcome and toxicity to checkpoint immunotherapy

Milotay G. et al, (2024)

Identification and validation of a machine learning model of complete response to radiation in rectal cancer reveals immune infiltrate and TGFβ as key predictors.

Domingo E. et al, (2024), EBioMedicine, 106

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.

Malla SB. et al, (2021), Clin Cancer Res, 27, 288 - 300